Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. [PDF]
, 2019 BackgroundPALOMA-2 confirmed that first-line palbociclib + letrozole improved progression-free survival (hazard ratio, 0.58; 95% confidence interval, 0.46-0.72) in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor ...
Diéras, Véronique +11 more
core
Triple positive breast cancer. A distinct subtype? [PDF]
, 2015 Breast cancer is a heterogeneous disease, and within the HER-2 positive subtype this is highly exemplified by the presence of substantial phenotypical and clinical heterogeneity, mostly related to hormonal receptor (HR) expression.
A. Cassano +19 more
core +1 more source
Cell Proliferation, Volume 59, Issue 3, March 2026.We generated endocrine‐resistant BC cell lines and identified CLEC3A, PCDH10, and ST3GAL1 as key endocrine‐resistant genes. More importantly, we validated their role in mediating resistance through PI3K‐AKT signalling and developed a predictive ERS with strong clinical relevance.
Liqin Ping +7 more
wiley +1 more source
Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle. [PDF]
, 2017 In this issue of Cancer Cell, Hydbring and colleagues define a novel class of microRNAs (miRNAs), deemed cell-cycle-targeting miRNAs, that target several cyclins/CDKs, reduce tumor cell growth, and induce apoptosis.
Knudsen, Karen E., Schiewer, Matthew J.
core +2 more sources
Sex Differences in Cancer Immunotherapy—Clinical Evidence and Mechanisms With a Focus on NSCLC
Immunological Reviews, Volume 338, Issue 1, March 2026.ABSTRACT Accumulating evidence suggests that the immune system shows subtle but relevant differences between men and women. These differences may have an impact on cancer development and TME composition as well as responses to and adverse events elicited by immunotherapies.
Eva Krieghoff‐Henning +4 more
wiley +1 more source
Preventative therapies for healthy women at high risk of breast cancer [PDF]
, 2014 Licensed under the Creative Commons Attribution Non-Commercial ...
Sestak, I
core +3 more sources
BMC Pregnancy and ChildbirthBackground Overweight women undergoing IVF treatment have lower success rates. Letrozole, an aromatase inhibitor, has been used as an adjunct for IVF treatment, but its specific effects in overweight women have not been investigated.
Jing Lin +5 more
doaj +1 more source
The relationship between oestrogen receptor-alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer [PDF]
, 2017 Aims: Although the role of phosphorylation of oestrogen receptor (ER) at serines 118 (p-S118) and 167 (p-S167) has been studied, the relationship between p-S118, p-S167 and the tumour microenvironment in ER-positive primary operable ductal breast ...
Arnold +38 more
core +1 more source
Journal of Pharmaceutical Analysis, 2016 A rapid and sensitive ultra performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) method is described for determination of letrozole in human plasma. Following solid phase extraction (SPE) of letrozole and letrozole-d4 on Orochem DVB-LP
Pravin G. Vanol +5 more
doaj +1 more source
Effect of Aromatase Inhibitor Letrozole on the Placenta of Adult Albino Rats: A Histopathological, Immunohistochemical, and Biochemical Study [PDF]
Iranian Journal of Medical SciencesBackground: Letrozole, an aromatase inhibitor, has recently been introduced as the preferred treatment option for ectopic pregnancy. To date, no study has investigated the effect of letrozole alone on placental tissue. The present study aimed to evaluate
Mohamed Ali Alabiad +10 more
doaj +1 more source